Intracranial atherosclerosis (ICAS) is one of the most frequent causes of stroke worldwide and has a high incidence of recurrent stroke. The therapeutic approaches for treating this high-risk disease have been evolving over time. The most recent, evidence-based approach is to focus on aggressive medical management of vascular risk factors and includes short-term dual antiplatelet treatment for 90 days followed by antiplatelet monotherapy. The role of endovascular therapy in the treatment of ICAS has not been established and is currently reserved only for patients who have failed aggressive medical management with recurrent ischemic events. There are no currently recommended surgical options to treat ICAS; however, investigational treatments such as encephaloduroarteriosynagiosis (EDAS) may hold promise. Despite aggressive medical management with short-term dual antiplatelet therapy, there remains a subset of patients with severe ICAS who will have recurrence of ischemic events. Further research is needed to better identify this high-risk subset and develop novel treatments to prevent further stroke and death.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11936-015-0369-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS) is a rare mature T-cell non-Hodgkin lymphoma (NHL) seen in both children and adults. While it is the most common non-anaplastic mature T-cell lymphoma of childhood, it is quite rare and therefore, the standard of care remains largely undefined. It is a disease characterized by clinical and pathological heterogeneity and is generally associated with an aggressive clinical course and poor prognosis in adults.
View Article and Find Full Text PDFPRIMARY CUTANEOUS CD8+ AGGRESSIVE EPIDERMOTROPIC CYTOTOXIC T-CELL LYMPHOMA WITH NOVEL FGFR1 FUSION TREATED WITH PEMIGATINIB.
Blood Adv
January 2025
Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States.
Pancreatic stellate cell: Update on molecular investigations and clinical translation in pancreatic cancer.
Int J Cancer
January 2025
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Early Drug Development Center, Peking University Cancer Hospital and Institute, Beijing, China.
Pancreatic cancer is a particularly aggressive tumor, distinguished by the presence of a prominent collagenous stroma and desmoplasia that envelops the tumor cells. Pancreatic stellate cell (PSC) contributes to the formation of a dense fibrotic stroma and has been demonstrated to facilitate tumor progression. As the significance of PSCs is increasingly revealed, more explorations are focused on the complex molecular mechanisms and tumor-stromal crosstalk in order to guide potential therapeutic approaches through deactivating or reprogramming PSCs.
View Article and Find Full Text PDFCommon and distinct neural underpinnings of the association between childhood maltreatment and depression and aggressive behavior.
BMC Psychiatry
January 2025
College of Artificial Intelligence, Southwest University, Chongqing, China.
Background: Although childhood maltreatment (CM) is widely recognized as a transdiagnostic risk factor for various internalizing and externalizing psychological disorders, the neural basis underlying this association remain unclear. The potential reasons for the inconsistent findings may be attributed to the involvement of both common and specific neural pathways that mediate the influence of childhood maltreatment on the emergence of psychopathological conditions.
Methods: This study aimed to delineate both the common and distinct neural pathways linking childhood maltreatment to depression and aggression.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!